Dietary fat supplement trial for A-T

Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision and speech. The condition can also result in a weakened immune system with frequent infections and an increased risk of cancers such as leukemia and lymphoma. A dietary fat supplement could improve the prognosis and quality of life for Australian children living A-T.

This innovative trial aims to treat mitochondrial dysfunction in A-T using a novel form of anaplerosis.

Children and adults with A-T across Australia are participating in the trial launched by the Federal Health Minister, The Hon. Greg Hunt MP, in 2022.

Redenlab are providing speech, language and mealtime assessments for the children, adolescents and adults in the trial.

For more information, click here.

Related Post

  • Posted on 24 October, 2023
    Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic options for...
    • Posted on 24 October, 2023
      Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination difficulties. SCA1...
      • Posted on 24 October, 2023
        Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes...